CanSino's revenue expected to hit RMB840 million in 2024, with market value of RMB8-10 billion. Approval for PCV13i expected in early 2025. Future new pandemic/potential licensing deals are catalysts
What is covered in the Full Insight:
Introduction to CanSino Biologics
2024 Performance Overview
PCV13i Vaccine Approval Outlook
Financial Predictions for 2025 and Beyond
Potential Catalysts for Stock Price
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.